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We analyze the impact of cyclosporine (CsA) levels in the development of acute graft-versus-host disease (aGVHD) after reduced
intensity conditioning allogeneic hematopoietic transplantation (allo-RIC). We retrospectively evaluated 156 consecutive patients
who underwent HLA-identical sibling allo-RIC at our institution. CsA median blood levels in the 1st, 2nd, 3rd and 4th weeks after
allo-RIC were 134 (range: 10–444), 219 (54–656), 253 (53–910) and 224 (30–699) ng/mL; 60%, 16%, 11% and 17% of the patients had
median CsA blood levels below 150 ng/mL during these weeks. 53 patients developed grade 2–4 aGVHD for a cumulative incidence
of 45% (95% CI 34–50%) at a median of 42 days. Low CsA levels on the 3rd week and sex-mismatch were associated with the
development of GVHD. Risk factors for 1-year NRM and OS were advanced disease status (HR: 2.2, 𝑃 = 0.02) and development of
grade 2–4 aGVHD (HR: 2.5,𝑃 < 0.01), while there was a trend for higher NRM in patients with a lowmedian CsA concentration on
the 3rd week (𝑃 = 0.06). These results emphasize the relevance of sustaining adequate levels of blood CsA by close monitoring and
dose adjustments, particularly when engraftment becomes evident. CsA adequate management will impact on long-term outcomes
in the allo-RIC setting.
1. Introduction
Myeloablative allogeneic hematopoietic cell transplantation
is the standard of care therapy for patients with several hema-
tologic malignancies, but its high treatment-relatedmortality
(TRM) frequently counterbalances its beneficial effects. Cur-
rently, reduced intensity conditioning (RIC) allows allogeneic
transplantation in patients otherwise considered ineligi-
ble because of advanced age or associated comorbidities.
Although early TRM is reduced with RIC regimens, the
development of graft-versus-host disease (GVHD) remains
an important cause of transplant related morbidity and mor-
tality [1–3].
Posttransplantation administration of immunosuppres-
sive agents remains the most widely used strategy to prevent
GVHD. A calcineurin inhibitor, mainly Cyclosporine-A
(CsA) in combination with a second drug, remains the most
common approach to prevent the occurrence of GVHD [4].
Several studies on myeloablative conditioning allogeneic
transplantation have shown that low whole blood concentra-
tions of CsA during the periengraftment period can strongly
affect the incidence of grade 2–4 acute GVHD (aGVHD)
[5, 6]. The impact of CsA levels in allo-RIC setting has been
less studied and justified the investigation reported here.
Accordingly, this study evaluated the impact of CsA levels on
the development of moderate to severe aGVHD, TRM,
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2014, Article ID 620682, 7 pages
http://dx.doi.org/10.1155/2014/620682
2 Mediators of Inflammation
and overall survival (OS) in a cohort of consecutive HLA-
identical sibling allo-RIC recipients.
2. Patients and Methods
2.1. Patients. We analyzed the data of 156 consecutive adult
patients included in two prospective allo-RIC cohorts from
our center transplanted between April 1999 and January 2010.
All patients were diagnosed with hematological malignancies
and received granulocyte-colony stimulating factor (G-CSF-)
mobilized peripheral blood stem cells from HLA-identical
siblings without in vivo/ex vivo T-cell depletion. HLAmatch-
ing was performed by low resolution techniques for HLA A
and HLA B and at the allelic level for HLA-DRB1 [7]. All par-
ticipants gave written informed consent and the studies were
approved by the national and local ethics committees.
2.2. Transplant Conditioning and GVHD Prophylaxis. The
conditioning regimen consisted of intravenous fludarabine
150mg/m2 or its equivalent oral doses (200mg/m2) com-
bined with either targeted doses of oral busulfan 10mg/kg
(8mg/kg for patients >65 years) for myeloid malignancies or
melphalan 140mg/m2 (70mg/m2 for patients >65 years) for
lymphoid malignancies. GVHD prophylaxis administered
was CsA plus either mycophenolate mofetil (MMF) or short
course methotrexate (MTX). CsA was started on day −7 in
most patients and administered at an initial dose of 1.5mg/kg/
12 h as a 2-hour infusion and then adjusted tomaintain blood
levels of 200–300 ng/mL. CsAwas switched to an oral formu-
lation at a ratio of 1 : 1 when patients were able to tolerate oral
intake.
From 1999 to 2003, MTX was administered on days +1,
+3, and +6 (10mg/m2) and folinic acid rescue was admin-
istered 24 h after each dose (𝑛 = 121, 78%). In 2004 MTX
was substituted for MMF (𝑛 = 35, 22%) in an effort to reduce
MTX-related toxicity. MMFwas started on day 0 (at least 10 h
after the infusion of progenitors) at a dose of 15mg/kg/8 h and
continued until day +30, when it was tapered in the absence
of aGVHD. As we have described previously [8, 9] and con-
firmed again in our patient population, the use of CsA+MTX
versus CsA+MMF or conditioning with busulphan versus
melphalan had no impact on the occurrence of grade 2–4
aGHVD; so we analyzed all the patients as a whole group.
2.3. Cyclosporine Dose Adjustment and GVHD Assessment.
CsA whole-blood concentration was measured by radioim-
munoassay [10] at least twice weekly during the first four
weeks after transplantation. Blood samples were collected 12
hours after the prior dose, immediately before the morning
dose. According to our current practice, when levels were
between 100 and 200 ng/mL the dose was increased by 25%. If
CsA concentrations were below 100 ng/mL and there was no
renal impairment the dose was increased by 50%. When the
blood concentrations were between 301 and 450 or 451 and
600 ng/mL the dose was decreased by 25% and 50%, respec-
tively. If blood concentrations exceeded 601 ng/mL the next
dose was omitted and the drug was restarted at half the dose.
Renal and liver function and electrolyte concentrations were
monitored daily during admission and at outpatient visits.
When kidney impairment occurred (defined as a decrease of
>25% of base-line glomerular filtration rate (GFR)) the CsA
dose was decreased by 25%. If there were no changes in renal
function, the drug was maintained in reduced doses and
administered as a 24 h continuous infusion. When severe
renal failure occurred (defined as decrease in GFR >50%),
CsAwas stopped until the renal function recovered, irrespec-
tive of the CsA blood levels.
CsA was also discontinued in case of severe thrombotic
microangiopathy, defined as the presence of 2 or more schis-
tocytes per high power field on peripheral smear with con-
current increased serum lactate dehydrogenase and renal or
neurological dysfunction without other explanations or pos-
itive direct Coombs’ test result.
Whenever CsA was stopped due to any severe compli-
cation, steroids were introduced at a dose of 2mg/kg/day
of prednisone. The dose of steroids was maintained or
slowly tapered until the complications resolved or markedly
improved; CsA was then restarted at a lower dose, or another
immunosuppressive drug was initiated if CsA could not be
reinitiated (MMF in most cases).
Diagnosis of aGVHD was based on clinical findings and
confirmed with histological evaluation of affected organ(s).
The overall grading followed the Przepiorka standard criteria
[11]. Anti-infectious prophylaxis was performed with acy-
clovir, quinolones (norfloxacin or ciprofloxacin), and flu-
conazole. Trimethoprim-sulfamethoxazole or nebulized pen-
tamidinewere also used as prophylaxis for at least sixmonths.
G-CSF was not routinely administered. Serial serum moni-
toring of Aspergillus galactomannan was performed in all
patients since 2004 [12]. A preemptive strategy against cyto-
megalovirus guided by antigenemia or PCR was performed,
as described elsewhere in details [13].
2.4. Risk Assessment. Advanced disease status was defined as
acute leukemia in ≥2nd complete response (CR), myelo-
proliferative disease in accelerated/blast phase or ≥2nd CR,
Hodgkin’s disease and follicular lymphoma in ≥3rd CR, and
large B-cell lymphoma or multiple myeloma in ≥2nd CR.
Patients with partial response (PR) or persistent disease at
transplantation (except for MM) were also considered as
advanced disease status.
2.5. Statistical Considerations. The primary endpoint of the
study was to assess the effect of Cyclosporine concentrations
on the development of 2–4 aGVHD. The median concentra-
tion of CsA blood levels during a given week was calculated
for each patient using the different concentrations obtained
during that week, as previously reported [5, 14]. The median
CsA in different weeks was compared with the ANOVA tests.
The impact of CsA levels on posttransplant outcomeswas cal-
culated treating this variable as a time-dependent covariate
with the event occurring at the onset of aGVHD. Overall
survival (OS) and the cumulative incidence of nonrelapse
mortality were secondary endpoints.
Univariate analyses of the association of various clinical
risk factors with posttransplantation outcomes were calcu-
lated using univariate Cox regression models, whereas the
Mediators of Inflammation 3
log-rank test was used for OS.Multivariate analyses were per-
formedbyCoxproportional hazards regression, and variables
with a 𝑃 value < 0.1 in the univariate testing were included.
𝑃 values < 0.05 were considered statistically significant, and
the hazard ratios (HRs) and their 95% confidence intervals
(95% CIs) were calculated. The assumption of proportional
hazards over time was tested for all explanatory covariates by
using a time-dependent covariate and the analysis of aGVHD
and NRM were calculated taking into account relapse as
a competing event [15–17]. Survival was estimated by the
Kaplan-Meier method, and comparisons of actuarial curves
were made with the log-rank test. All statistical analyses were
performed using SPSS version 19.0 with the exception of the
cumulative incidence analyses which were performed with
NCSS 2004 (Number Cruncher Statistical System, Kaysville,
UT).
3. Results
3.1. Patient and Transplant Characteristics. Characteristics of
the patients are shown in detail on Table 1. The main reasons
for receiving RIC instead of myeloablative conditioning were
age >55 years (𝑛 = 77, 49%), multiple prior therapy lines or
autologous HCT (𝑛 = 24, 15%), and significant medical
comorbidities (𝑛 = 10, 6%). Forty-five patients (29%) pre-
sented more than one of the previous circumstances. Fifty-
three patients with a myeloid malignancy (35%) received
fludarabine-busulfan conditioning, while the 103 patients
(65%) with lymphoid malignancies received fludarabine-
melphalan.Themedian follow-up of survivors was 67 (5–121)
months.
3.2. Cyclosporine Levels. Table 2 shows in details the results of
the CsA levels during the first 4 weeks after allo-RIC. The
median blood concentration of CsA in the 1st week after
transplantationwas lower than in the 2nd, 3rd, and 4thweeks,
with values of 134 (range: 10–444), 219 (range: 54–656), 253
(range: 53–910), and 224 (range: 30–699) ng/mL, respectively
(𝑃 < 0.001). Eighty-nine (60%), 24 (16%), 16 (11%), and 21
(17%) patients had median CsA levels below 150 ng/mL dur-
ing these weeks. Only 15% of patients had CsA levels within
the “optimal” range of 200–300 ng/mL in the first week, while
around 45% of the cases had a median level within this opti-
mal range from the 2nd to the 4th week after transplantation.
In our series 77 patients began CsA on day −7.We did not
find significant differences in CsA levels during the first week
between this group and those who started CsA in day −1, but
the number of patients is small, and these results would need
a proper study.
3.3. Incidence and Risk Factors for Acute Graft versus Host
Disease. 55 patients (36%) developed 2–4 aGVHD for a
cunulative incedence of 45% (34–50%) at day +180. aGVHD
appeared at a median time of 42 (range: 16–185) days after
allo-RIC. Further details of aGVHDare shown inTable 3.The
median CsA blood concentrations in the second and third
weeks after transplantation were lower in patients who devel-
oped grade 2–4 aGVHD than in the remainder (201 versus
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1501209060300
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
CsA levels during third week
G
ra
de
2
–4
ac
ut
e G
vH
D
<150
>150
P = 0.01
Figure 1: Cumulative incidence of grades 2–4 aGVHD. Cumulative
incidence of grades 2–4 aGVHD depending on CsA concentration
during the thirdweek posttransplantation.Thepatients withmedian
CsA levels lower than 150 ng/mL are included in the group “LowCsA
levels.” CsA: cyclosporine; aGVHD: acute graft versus host disease.
237 ng/mL, 𝑃 = 0.01, and 248 versus 283 ng/mL, 𝑃 = 0.06
shown in Figure 1); in contrast, there were no significant dif-
ferences in the levels when analyzed on the first (143 versus
139, 𝑃 = 0.7) and fourth weeks (226 versus 254, 𝑃 = 0.2).
In univariate analysis the variables associated with a higher
incidence of grade 2–4 aGVHD were sex-mismatch (female
donor to male recipient versus other combinations (𝑃 <
0.01)) and low median CsA blood levels (defined as median
CsA levels below 150 ng/mL) in the second (𝑃 = 0.02) and
third (𝑃 = 0.01) weeks after allo-RIC. CMV status, disease
phase at SCT, age of the recipient, donor age, conditioning
(busulphan versus melphalan), GVHD prophylaxis with
MMF versus MTX, and CsA levels in the first and fourth
weeks after transplantation were not associated with aGVHD
(detailed in Table 4). In multivariate analysis the only signif-
icant variables associated with grade 2–4 aGVHD were low
CsA concentration during the third week after transplanta-
tion and female-to-male sex-mismatch, as shown in Table 4.
3.4. Toxicity and Early Discontinuation of Cyclosporine. Renal
impairment occurred in 49 patients (31%) during the first 5
weeks after transplantation. CsA was the only cause of renal
failure in 35 of these patients (71%). Six patients (3.8%) devel-
oped a thrombotic microangiopathy (TMA). The median
concentration in the 7 days before the onset of renal failure
or TMA did not differ in patients with CsA-related toxicity
and those with other causes of renal dysfunction (244 versus
211, resp.; 𝑃 = 0.2). The median CsA during the first month
in patients without renal impairment was 205 ng/mL (range
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Table 1: Patients’ characteristics.
Characteristics Population (𝑛 = 156)
Median age, years (range) 52 (17–69)
Patient sex, 𝑛 (%)
Female 64 (41%)
Sex-mismatch, 𝑛 (%)
Female to male 41 (26.3%)
Diagnosis, 𝑛 (%)
AML/MDS 28 (18%)/17 (11%)
ALL 5 (3%)
NHL/CLL 30 (20%)/11 (7%)
HD 23 (15%)
MM 33 (21%)
CML/other CMPN 7 (5%)/2 (1%)
ECOG, 𝑛 (%)
0 135 (86.5%)
1 10 (6.4%)
2 11 (7.1%)
Reason for RIC, 𝑛 (%)
Advanced age 77 (49.4%)
Multiple prior lines of treatment
and/or prior transplantation 24 (15.4%)
Comorbidities and/or ECOG >1 10 (6.4%)
More than one reason 45 (28.8%)
Disease status, 𝑛 (%)
Early phase 72 (46%)
Advanced phase 84 (54%)
Renal impairment before SCT, 𝑛 (%)
None 129 (83%)
GFR 50–60 mL/min 16 (10%)
GFR 40–50 mL/min 9 (6%)
GFR < 40mL/min 2 (1.3%)
CMV serostatus
(donor and receptor negative), 𝑛 (%) 10 (6.4 %)
Conditioning regimen, 𝑛 (%)
Fludarabine-melphalan 103 (65%)
Fludarabine-busulfan 53 (35%)
CD34+ × 10E6/kg infused, median
(range) 6.7 (1.6–15.6)
GVHD prophylaxis, 𝑛 (%)
CsA-MTX 121 (77.6%)
CsA-MMF 35 (22.4%)
Follow-up for survivors in months:
median (range) 67 (5–121)
Notes: AML: acutemyeloid leukemia;MDS:myelodisplastic syndrome; ALL:
acute lymphatic leukemia; NHL: non-Hodgkin lymphoma; CLL: chronic
lymphoid leukemia; HD: Hodgkin disease; MM: multiple myeloma; CML:
chronic myeloid leukemia; CMPN: chronic myeloproliferative neoplasms;
GFR: glomerular filtration rate.
Table 2: Description of Csa levels during the first four weeks after
stem cell transplantation.
CsA blood concentration; median
(range) ng/mL
First week 134 (10–444)
Second week 219 (54–656)
Third week 253 (53–910)
Fourth week 224 (30–699)
Patients with CsA median levels in the
optimal range (200–300 ng/mL); 𝑛 (%)
First week 22/149 (15%)
Second week 67/153 (44%)
Third week 66/148 (45%)
Fourth week 53/123 (43%)
Patients with one or more CsA blood
level(s) below 150 ng/mL; 𝑛 (%)
First week 124 (83%)
Second week 51 (33%)
Third week 28 (19%)
Fourth week 26 (21%)
Patients with CsA median levels lower
than 150 ng/mL 𝑛 (%)
First week 89 (60%)
Second week 24 (16%)
Third week 16 (11%)
Fourth week 21 (17%)
Note: CsA: cyclosporine A.
Table 3: Incidence and characteristics of graft versus host disease.
Patients with aGVHD, 𝑛 (%)
Grade 1 32 (20.5%)
Grade 2 32 (20.5%)
Grade 3 18 (11.5%)
Grade 4 5 (3.2%)
Incidence of aGVHD, %, (95% CI)
Any grade 58% (50–64%)
Grade 2–4 45% (34–50%)
Organs involved, 𝑛 (%)
Skin 75 (48%)
Gastrointestinal tract 45 (29%)
Liver 45 (29%)
Day onset of aGVHD, median (range)
Any grade 43 (12–185)
Grades 2–4 42 (16–185)
Note: aGVHD: acute graft versus host disease.
92–457) compared to 208 ng/mL in those patients who pre-
sented nephrotoxicity (range: 10–611; 𝑃 = 0.4).
CsA blood concentration was higher than 300 ng/mL in
only 9/49 (18%) cases with renal impairment. Interestingly
there were not differences in the incidence of aGVHD bet-
ween patients who developed nephrotoxicity and those with-
out renal impairment (𝑃 = 0.4).
Mediators of Inflammation 5
Table 4: Univariate and multivariate analysis for aGVHD.
Grade 2–4 aGVHD
Variable Univariate analysis Multivariate analysis
𝑃 HR CI 95% 𝑃
Sex-mismatch (female to male) 0.01 2.5 1.5–4.3 0.01
High CsA concentration
Second week 0.02 NS
Third week 0.01 0.99 0.98-0.99 0.03
Patient sex (male) 0.01 NS
The patients with median CsA levels higher than 150 ng/mL are included in the group “high CsA concentration.”
Notes: LR: log-rank; HR: hazard ratio; NS: not statistically significant.
CMV status, disease status at SCT, age of the recipient, conditioning regimen, immunosuppressive schedule, and CsA levels during the first and fourth week
after transplantation were not associated with acute GVHD in univariate analysis (𝑃 > 0.1).
Table 5: Univariate and multivariate analysis for nonrelapse mortality and overall survival.
Nonrelapse mortality Overall survival
Variables Univariate analysis Multivariate cox regression Univariate analysis Multivariate cox regression
𝑃 value HR (95% CI) 𝑃 𝑃 value HR (95% CI) 𝑃 value
Sex-mismatch (female to male) <0.01 NS 0.02 NS
Advanced disease status 0.01 2.2 (1.3–4.3) 0.01 0.02 2.2 (1.1–4.3) 0.02
Low median CsA levels in 3rd week∗ 0.04 NS (0.06) 0.08 NS
Renal impairment∗ 0.06 NS 0.08 NS
Grade 2–4 aGVHD∗ <0.01 2.5 (1.5–4.4) 0.01 <0.01 2.5 (1.4–4.4) <0.01
Note: CsA: cyclosporine A; aGVHD: acute graft versus host disease; HR: hazard ratio; CI: confidence interval.
∗Variables analyzed as time-dependent covariates.
3.5. NonrelapseMortality andOverall Survival. Table 5 shows
the variables identified as risk factors for the 1-year NRM and
OS in univariate and multivariate analyses. The cumulative
incidence of NRM for the whole group at +180 days and 1 year
was 15% (95% CI: 11–22) and 20% (95% CI: 15–28), respec-
tively. In the multivariate analysis the variables found to have
a negative impact on NRM were advanced disease status at
transplantation (HR 2.2,𝑃: 0.01) and development of grade 2–
4 aGVHD (HR: 2.5, 𝑃: 0.01), whereas low median CsA blood
levels on the third week after transplantation showed a trend
as additional independent risk factor for NRM (𝑃: 0.06).
The 1-year and 5-year probability ofOSwere 67% (95%CI:
59–74.5%) and 45% (95% CI: 33–51%), respectively. Relapse
(39%) was the main cause of death, followed by GVHD
(aGVHD: 14 (16%), chronic GVHD: 10 (11.5%)), and infec-
tious complications (𝑛 = 16, 18%). The median time to death
from any cause was 7.8 months (range: 0.2–94 months). In
multivariate analysis, the only two variables associated to
adverse OS were advanced disease status at SCT (HR: 2.2,
𝑃: 0.02) and development of grade 2–4 aGVHD (HR 2.5,
𝑃 < 0.01).
4. Discussion
The current study found that, despite close surveillance, the
median CsA levels were outside the desired range in a pro-
portion of patients during the early posttransplant period. Of
note, low median levels of CsA during the third week post-
SCT were associated with a higher risk of grade 2–4 aGVHD
and a trend towards increased risk of NRM.
Despite significant improvements in terms of therapeutic
drug monitoring in the last years, one of the most important
and unexpected finding in the current study was the substan-
tial proportion of patients with low levels of CsA in the first
weeks post-SCT. Despite continuous changes in the dose of
CsA, approximately 15% of the patients maintained low levels
of CsA during the following three weeks.
Possible explanations for these findings could be the use
of short perfusion of CsA, compared to the 8 or 24 h continu-
ous infusion administered in other centers, a less stringent
monitoring of CsA levels (every other day in Song et al.’s
study) [14, 18, 19] or a conservative approach when CsA dose
had to be increased in those patients with very low CsA pre-
vious concentrations. In our series, there appears to be no
benefit in startingCsAon day−7 instead of−1, supporting the
results by Lanino et al. [20].
Renal impairment is a well-known potential toxicity of
CsA that appears to be dose related and reversible [21, 22].The
31% rate of renal impairment during the firstmonth post-SCT
in this cohort of patients is similar to previous reports [23,
24]. CsA was considered responsible of renal function im-
pairment in 71% of the cases. Surprisingly, there were no dif-
ferences in the median CsA concentration the week prior to
the onset of renal failure compared to the blood levels in
patients who maintained a normal kidney function, even in
the 71% of patients who were considered to have CsA-related
renal failure.
6 Mediators of Inflammation
The incidence of grade 2–4 aGVHD in our population
(45% (95%CI 34–50%)) was similar to previous studies in the
allo-RIC setting [25] and it was statistically significantly
higher in patients with low median CsA levels during the
third week post-SCT. This finding may be due to the need of
having therapeutic levels of CsA especially during the time of
lymphohematopoietic recovery, which was around day +15
(range: 10–29) in our series. This finding is similar to a
recently published study analyzing the impact of tacrolimus
levels after stem cell infusion (OR: 0.76, 95% CI: 0.58–0.98,
𝑃 < 0.05 for those patients with high concentrations of the
calcineurin inhibitor in the third week post-SCT) [26]. Other
studies have shown the relationship between low CsA con-
centrations and increased risk of aGVHD, but conflicting
findings about the moment in which this association is more
important have been reported. A recent publication by
Malard et al. [6], analyzing a series of patients receiving both
conventional and RIC regimens, found that the CsA blood
levels in the first week after graft infusion was the strongest
risk factor for severe aGVHD (𝑃 = 0.012, RR = 0.24).
Although the development of RIC regimens has allowed
patients who are ineligible for standard Allo-SCT to poten-
tially benefit from allogeneic therapy, NRM remains a signifi-
cant obstacle to the success of Allo-RIC. Our study found that
advanced disease status at transplantation and development
of grade 2–4 aGVHDwas strongly related to higherNRMand
lower OS. Taken together, the current study suggests that im-
proving CsA monitoring and dose adjustments may lead to a
reduction of grade 2–4 aGVHD and even decrease NRM in
the RIC setting.
Themain limitations of our study include its retrospective
nature and the evaluation of median CsA concentrations
instead of the area under the curve over time [27, 28], a much
more precise monitoring strategy which, however, is difficult
to implement in daily clinical practice. In conclusion, the cur-
rent study suggests that low median CsA concentrations in
the early posttransplant period are associated with a higher
incidence of grade 2–4 aGVHD in patients receiving an allo-
RIC, suggesting thatmaintaining highCsA blood levels in the
absence of organ toxicity may translate into lower risk of
grade 2–4 aGVHD and improved long-term outcomes.
Conflict of Interests
None of the coauthors has reported any conflict of interests
of any kind with any information contained in the paper.
References
[1] R. Martino, D. Valca´rcel, S. Brunet, A. Sureda, and J. Sierra,
“Comparable non-relapse mortality and survival after HLA-
identical sibling blood stem cell transplantationwith reduced or
conventional-intensity preparative regimens for high-risk mye-
lodysplasia or acute myeloid leukemia in first remission,” Bone
Marrow Transplantation, vol. 41, no. 1, pp. 33–38, 2008.
[2] D. Valca´rcel, R. Martino, D. Caballero et al., “Sustained remis-
sions of high-risk acute myeloid leukemia and myelodysplas-
tic syndrome after reduced-intensity conditioning allogeneic
hematopoietic transplantation: chronic graft-versus-host dis-
ease is the strongest factor improving survival,” Journal of Clin-
ical Oncology, vol. 26, no. 4, pp. 577–584, 2008.
[3] G. K. Melve, E. Ersvssr, A. O. Kittang, and O. Bruserud, “The
chemokine system in allogeneic stem-cell transplantation: a
possible therapeutic target?” Expert Review of Hematology, vol.
4, no. 5, pp. 563–576, 2011.
[4] R. E.Handschumacher,M.W.Harding, J. Rice, R. J. Drugge, and
D.W. Speicher, “Cyclophilin: a specific cytosolic binding protein
for cyclosporinA,” Science, vol. 226, no. 4674, pp. 544–547, 1984.
[5] N. Izumi, T. Furukawa, N. Sato et al., “Risk factors for acute
graft-versus-host disease after allogeneic hematopoietic stem
cell transplantation: retrospective analysis of 73 patients who
received cyclosporin A,” Bone Marrow Transplantation, vol. 40,
no. 9, pp. 875–880, 2007.
[6] F. Malard, R. M. Szydlo, E. Brissot et al., “Impact of cyclos-
porine-A concentration on the incidence of severe acute graft-
versus-host disease after allogeneic stem cell transplantation,”
Biology of Blood and Marrow Transplantation, vol. 16, no. 1, pp.
28–34, 2010.
[7] A. Bontadini, “HLA techniques: typing and antibody detection
in the laboratory of immunogenetics,” Methods, vol. 56, no. 4,
pp. 471–476, 2012.
[8] J. Delgado, A. Marco, E. Moreno et al., “Reduced-intensity con-
ditioning allogeneic hematopoietic cell transplantation using
oral fludarabine as part of the conditioning regimen,” Cytother-
apy, vol. 11, no. 3, pp. 356–361, 2009.
[9] J. L. Pin˜ana, D. Valca´rcel, F. Ferna´ndez-Avile´s et al., “MTX or
mycophenolate mofetil with CsA as GVHD prophylaxis after
reduced-intensity conditioning PBSCT from HLA-identical
siblings,” BoneMarrow Transplantation, vol. 45, no. 9, pp. 1449–
1456, 2010.
[10] D. J. Andrews and R. Cramb, “Cyclosporin: revisions in mon-
itoring guidelines and review of current analytical methods,”
Annals of Clinical Biochemistry, vol. 39, no. 5, pp. 424–435, 2002.
[11] D. Przepiorka, D. Weisdorf, P. Martin et al., “1994 consensus
conference on acute GVHD grading,” Bone Marrow Transplan-
tation, vol. 15, no. 6, pp. 825–828, 1995.
[12] R. Martino and M. Subira`, “Invasive fungal infections in hema-
tology: new trends,” Annals of Hematology, vol. 81, no. 5, pp.
233–243, 2002.
[13] J. L. Pin˜ana, R. Martino, P. Barba et al., “Cytomegalovirus infec-
tion and disease after reduced intensity conditioning allogeneic
stem cell transplantation: single-centre experience,” Bone Mar-
row Transplantation, vol. 45, no. 3, pp. 534–542, 2010.
[14] Y. Kanda, R. Hyo, T. Yamashita et al., “Effect of blood cyclos-
porine concentration on the outcome of hematopoietec stem
cell transplantation from an HLA-matched sibling donor,”
American Journal of Hematology, vol. 81, no. 11, pp. 838–844,
2006.
[15] J. P. Klein, J. D. Rizzo, M.-J. Zhang, and N. Keiding, “Statistical
methods for the analysis and presentation of the results of bone
marrow transplants—part I: unadjusted analysis,” BoneMarrow
Transplantation, vol. 28, no. 10, pp. 909–915, 2001.
[16] J. P. Klein, J. D. Rizzo, M.-J. Zhang, and N. Keiding, “Statistical
methods for the analysis and presentation of the results of bone
marrow transplants—part 2: regression modeling,” Bone Mar-
row Transplantation, vol. 28, no. 11, pp. 1001–1011, 2001.
[17] E. L. Kaplan and P. Meier, “Nonparametric estimation from in-
complete observations,” Journal of the American Statistical Asso-
ciation, vol. 53, no. 282, pp. 457–481, 1958.
Mediators of Inflammation 7
[18] M.-K. Song, J.-S. Chung, Y.-M. Seol et al., “Influence of lactate
dehydrogenase and cyclosporine a level on the incidence of
acute graft-versus-host disease after allogeneic stem cell trans-
plantation,” Journal of KoreanMedical Science, vol. 24, no. 4, pp.
555–560, 2009.
[19] P. Martin, N. Bleyzac, G. Souillet et al., “Relationship between
CsA trough blood concentration and severity of acute graft-
versus-host disease after paediatric stem cell transplantation
from matched-sibling or unrelated donors,” Bone Marrow
Transplantation, vol. 32, no. 8, pp. 777–784, 2003.
[20] E. Lanino, R. Rondelli, F. Locatelli et al., “Early (day −7) versus
conventional (day −1) inception of cyclosporine-A for graft-
versus-host disease prophylaxis after unrelated donor hema-
topoietic stem cell transplantation in children. Long-term
results of an AIEOP prospective, randomized study,” Biology of
Blood and Marrow Transplantation, vol. 15, no. 6, pp. 741–748,
2009.
[21] J. L. Pin˜ana, D. Valca´rcel, R. Martino et al., “Study of kidney
function impairment after reduced-intensity conditioning allo-
geneic hematopoietic stem cell transplantation. A single-center
experience,” Biology of Blood and Marrow Transplantation, vol.
15, no. 1, pp. 21–29, 2009.
[22] W. M. Bennett and J. P. Pulliam, “Cyclosporine nephrotoxicity,”
Annals of Internal Medicine, vol. 99, no. 6, pp. 851–854, 1983.
[23] C. R. Parikh, B.M. Sandmaier, R. F. Storb et al., “Acute renal fail-
ure after nonmyeloablative hematopoietic cell transplantation,”
Journal of the American Society of Nephrology, vol. 15, no. 7, pp.
1868–1876, 2004.
[24] S. Kersting, S. V. Dorp, M.Theobald, and L. F. Verdonck, “Acute
renal failure after nonmyeloablative stem cell transplantation in
adults,” Biology of Blood and Marrow Transplantation, vol. 14,
no. 1, pp. 125–131, 2008.
[25] P. Satwani, L. Harrison, E. Morris, G. del Toro, and M. S. Cairo,
“Reduced-intensity allogeneic stem cell transplantation in
adults and children with malignant and nonmalignant diseases:
end of the beginning and future challenges,” Biology of Blood
and Marrow Transplantation, vol. 11, no. 6, pp. 403–422, 2005.
[26] T. Mori, J. Kato, T. Shimizu et al., “Effect of early posttransplan-
tation tacrolimus concentration on the development of acute
graft-versus-host disease after allogeneic hematopoietic stem
cell transplantation from unrelated donors,” Biology of Blood
and Marrow Transplantation, vol. 18, no. 2, pp. 229–234, 2012.
[27] M. Jin, W. Seto, T. Taylor, E. F. Saunders, J. Doyle, and L. L.
Dupuis, “Determination of initial i.v. CYAdosage to achieve tar-
get AUC values in pediatric hematopoietic stem cell transplant
patients,” Bone Marrow Transplantation, vol. 42, no. 7, pp. 455–
459, 2008.
[28] N. Duncan, J. Arrazi, S. Nagra, M. Cook, A. H. Thomson, and
C. Craddock, “Prediction of intravenous cyclosporine area
under the concentration-time curve after allogeneic stem cell
transplantation,”Therapeutic DrugMonitoring, vol. 32, no. 3, pp.
353–358, 2010.
